www.growopportunity.ca

Industry Updates News Medical Research
Strainprint takes first step in groundbreaking cannabis research


August 8, 2019
By Grow Opportunity staff

Topics
Strainprint Technologies Ltd. (CNW Group/Strainprint Technologies Ltd.)

Strainprint Technologies Ltd. said the first step to world-leading cannabis research has begun with the launch of its custom survey on the effects of cannabis for endometriosis sufferers.

The Toronto-based cannabis data company is collaborating with Gynica and Lumir Lab in Israel to conduct the world’s first international clinical study on cannabis treatments for endometriosis. On Aug. 7, Strainprint announced an online questionnaire about how women with endometriosis are using cannabis to treat their symptoms.

Cannabinoids have long been suggested as a common treatment for pain management. In fact, Vice-President of Research Michelle Arbus said many of Strainprint’s app users and community members are endometriosis sufferers themselves. The data gathered from their app users will give the research team a detailed picture of this practice.

“We believe many women will be eager to take part in this ground-breaking research,” said Arbus in a statement. “Our online Strainprint Community already provides a safe space to discuss endometriosis and cannabis treatment with fellow sufferers, and through this questionnaire… They will now have a chance to be pioneers in a study that could make medical history by helping others not only manage their symptoms, but also greatly improve their quality of life.”

The questionnaire was developed in partnership with Gynica’s senior scientist, Dr. Sari Prutchi Sagiv and will be accessible through an exclusive group on the Strainprint online community platform.

The group will allow participants share their experiences and gain to access to custom educational materials on endometriosis. The site currently hosts targeted support groups for endometriosis sufferers, in addition to dozens of other open topic specific forums related to cannabis.

“Our objective is to recruit suffering candidates to explore cannabis as a viable therapy in the hopes of developing improved diagnostics and treatments to those who are undertreated by current solutions,” said Moshe Hod, president of the European Association of Perinatal Medicine and professor of Obstetrics and Gynecology at Tel Aviv University medical school.

Survey participants must be 18 years or older and currently suffer from endometriosis. Once they register to the Strainprint Community, they can request access to an exclusive group, only open to questionnaire participants, giving them access to the questionnaire, forums, specialized endometriosis education materials and more.